Hernández ZA, Xolalpa PAV, Tejerina ME, Sánchez AF, Saulés RAS, Cervantes MAS, Hernández CME

Language: Spanish
References: 18
Page: 355-360
PDF size: 246.59 Kb.

ABSTRACT

Nosocomial infections represent a significant challenge for healthcare systems worldwide due to their impact on morbidity, mortality, and associated costs. This study analyzes the prevalence and incidence of nosocomial infections at Hospital Angeles México from January 2022 to June 2024. The most frequent types of infections, their anatomical location, the microorganisms involved, and their relationship with the use of medical devices were identified. These findings provide a basis for developing strategies to reduce the incidence of these infections in the hospital.

REFERENCES

1. World Health Organization. Global report on infection prevention and control. WHO; 2022.

2. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS et al. Impact of infections with antibiotic-resistant bacteria in Europe. Lancet Infect Dis. 2019; 19 (1): 56-66.

3. Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections – an overview. Infect Drug Resist. 2018; 11: 2321-2333.

4. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399 (10325): 629-655.

5. Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J et al. Changes in prevalence of health care–associated infections in U.S. hospitals. N Engl J Med. 2018; 379 (18): 1732-1744.

6. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2018; 377 (9761): 228-241.

7. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2020; 18 (3): 318-327.

8. Ramirez Barba EJ, Rosenthal VD, Higuera F, Oropeza MS, Hernández HT, López MS, et al. Device-associated nosocomial infection rates in intensive care units in four Mexican public hospitals. Am J Infect Control. 2006;34(4):244-247.

9. Secretaría de Salud de México. Informe Anual del Sistema Nacional de Vigilancia Epidemiológica. México: Secretaría de Salud; 2021.

10. Lugo-Zamudio GE, Cureño-Díaz MA. La resistencia antimicrobiana, una amenaza en tres dimensiones. Salud Publica Mex. 2023;65(4):323-324.

11. Ponce de León-Rosales SP, Molinar-Ramos F, Domínguez-Cherit G, Rangel-Frausto MS, Vázquez-Ramos VG. Prevalence of infections in intensive care units in Mexico: a multicenter study. Crit Care Med. 2000;28(5):1316-1321.

12. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478–1487.

13. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770-1780.

14. Cristina ML, Spagnolo AM, Giribone L, Demartini A, Sartini M. Epidemiology and prevention of healthcare-associated infections in geriatric patients: a narrative review. Int J Environ Res Public Health. 2021;18(10):5333.

15. Instituto Nacional de Estadística y Geografía (INEGI). Proyecciones de la Población de México y de las Entidades Federativas 2016-2050. México: INEGI; 2020. Disponible en: https://datos.gob.mx/busca/dataset/proyecciones-de-la-poblacion-de-mexico-y-de-las-entidades-federativas-2016-2050

16. Rawson TM, Moore LSP, Castro-Sánchez E, Charani E, Davies F, Satta G et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020; 75 (7): 1681-1684.

17. Hsu J. How COVID-19 is accelerating the threat of antimicrobial resistance. BMJ. 2020; 369: m1983.

18. Weiner-Lastinger LM, Abner S, Edwards JR, et al. The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020. Infect Control Hosp Epidemiol. 2022; 43 (1): 12-25.